HomeInsulin HumanInsulin Human + Tirzepatide

Does Insulin Human Interact with Tirzepatide?

Insulin Human and Tirzepatide have a major drug interaction according to U.S. FDA drug labeling data. Risk of hypoglycemia when initiating MOUNJARO; consider reducing insulin dose. The mechanism involves additive hypoglycemic effect. Patients taking both medications should consult their healthcare provider before starting, stopping, or changing the dosage of either drug. This information is based on official FDA drug labeling sourced from OpenFDA and the NIH National Library of Medicine.

Severity
Major
Insulin Human Class
Insulin
Tirzepatide Class
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Management
Close medical supervision required
Data Source
U.S. FDA via OpenFDA

How This Interaction Works

The interaction between Insulin Human and Tirzepatide occurs because additive hypoglycemic effect. Clinically, this means risk of hypoglycemia when initiating mounjaro; consider reducing insulin dose. This is classified as a major interaction, meaning it could cause serious harm if not properly managed. Your healthcare provider may need to adjust dosages, substitute one medication, or increase monitoring frequency.

What To Tell Your Doctor or Pharmacist

If you are taking Insulin Human and your doctor is considering prescribing Tirzepatide (or vice versa), make sure to:

  • Inform your doctor and pharmacist of all current medications, including over-the-counter drugs and supplements
  • Ask whether the benefits of combining these medications outweigh the risks for your specific situation
  • Ask what symptoms to watch for that would indicate the interaction is causing problems
  • Ask how frequently you should be monitored while these are co-prescribed
  • Ask whether any dosage adjustments are needed
  • Never stop or change either medication without first consulting your healthcare provider
💊 Insulin Human(Myxredlin)+💊 Tirzepatide(Zepbound)

Severity & Interaction Details

⚠️
major
Use with caution — major interaction
Serious risk of clinically significant harm. Generally avoid; if used, monitor closely.
Severity scale
MinorContra
On record
Yes
Drug A class
Insulin
Drug B class
Glucose-dependent Insulinotropic Polypeptide Receptor Agonist
Source
NLP:tirzepatide

What this means in plain English

Risk of hypoglycemia when initiating MOUNJARO; consider reducing insulin dose.

What the FDA label says

"Additive hypoglycemic effect"

📖 Source: NLP:tirzepatide

Share this result:XFacebookWhatsAppReddit
Add more drugs
Check Insulin Human and Tirzepatide against your full medication list

Most patients take more than two medications. CDI checks every pair across up to 20 drugs simultaneously — including OTCs and common supplements.

Add more drugs →

Data sourced from U.S. FDA drug labeling via openFDA and the NIH National Library of Medicine. For informational purposes only. Always consult your pharmacist or physician.